85 related articles for article (PubMed ID: 29763411)
1. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
Nagar S; Patel J; Stanford RH
Manag Care; 2018 May; 27(5):40-47. PubMed ID: 29763411
[TBL] [Abstract][Full Text] [Related]
2. Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies.
Palli SR; Xie B; Chastek B; Elliott CA; Bengtson LGS
J Manag Care Spec Pharm; 2021 Jul; 27(7):810-824. PubMed ID: 33764161
[No Abstract] [Full Text] [Related]
3. Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study.
Kozma CM; Paris AL; Plauschinat CA; Slaton T; Mackowiak JI
BMC Pulm Med; 2011 Dec; 11():61. PubMed ID: 22192866
[TBL] [Abstract][Full Text] [Related]
4. Adding tiotropium or long-acting β2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization.
Hanania NA; Settipane RA; Khoury S; Shaikh A; Dotiwala Z; Casciano J; Foggs MB
Allergy Asthma Proc; 2023 Nov; 44(6):413-421. PubMed ID: 37919843
[No Abstract] [Full Text] [Related]
5. Long-acting B-2 agonists (LABA) or long-acting muscarinic antagonists (LAMA): which one may be the first option in group A COPD patients?
Turan O; Ogan N; Bozkus F; Sarıoğlu N; Turan PA; Satıcı C
Eur J Clin Pharmacol; 2024 Jun; 80(6):847-853. PubMed ID: 38396308
[TBL] [Abstract][Full Text] [Related]
6. When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
Shin HJ; Kim YI; Kim Y; Lee CY; Ra SW; Moon JY; Jung KS; Yoo KH; Shin KC; Lim SC;
Chonnam Med J; 2023 Sep; 59(3):180-187. PubMed ID: 37840676
[TBL] [Abstract][Full Text] [Related]
7. Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study.
Shantakumar S; Pwu RF; D'Silva L; Wurst K; Kuo YW; Yang YY; Juan YC; Chan KA
BMC Pulm Med; 2018 Jan; 18(1):16. PubMed ID: 29368608
[TBL] [Abstract][Full Text] [Related]
8. Impact of Nonadherence to Inhaled Corticosteroid/LABA Therapy on COPD Exacerbation Rates and Healthcare Costs in a Commercially Insured US Population.
Davis JR; Wu B; Kern DM; Tunceli O; Fox KM; Horton J; Legg RF; Trudo F
Am Health Drug Benefits; 2017 Apr; 10(2):92-102. PubMed ID: 28626506
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium Bromide Attenuates Mucus Hypersecretion in Patients with Stable Chronic Obstructive Pulmonary Disease.
Yu S; Zhang C; Yan Z; Fang Q; Gao X
Comput Math Methods Med; 2021; 2021():1341644. PubMed ID: 34650619
[TBL] [Abstract][Full Text] [Related]
10. The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index.
Song Q; Zhou A; Lin L; Li X; Cheng W; Liu C; Peng Y; Zeng Y; Yi R; Liu Y; Li X; Chen Y; Cai S; Chen P
Front Pharmacol; 2023; 14():1131614. PubMed ID: 37521460
[No Abstract] [Full Text] [Related]
11. Missing potential opportunities to reduce repeat COPD exacerbations.
Melzer AC; Feemster LM; Uman JE; Ramenofsky DH; Au DH
J Gen Intern Med; 2013 May; 28(5):652-9. PubMed ID: 23225255
[TBL] [Abstract][Full Text] [Related]
12. LAMA improve tissue oxygenation more than LABA in patients with COPD.
Perez-Bogerd S; Van Muylem A; Zengin S; El Khloufi Y; Maufroy E; Faoro V; Malinovschi A; Michils A
J Appl Physiol (1985); 2024 May; ():. PubMed ID: 38722752
[TBL] [Abstract][Full Text] [Related]
13. Inhaled β-agonist does not modify sympathetic activity in patients with COPD.
Haarmann H; Mohrlang C; Tschiesner U; Rubin DB; Bornemann T; Rüter K; Bonev S; Raupach T; Hasenfuß G; Andreas S
BMC Pulm Med; 2015 Apr; 15():46. PubMed ID: 25924990
[TBL] [Abstract][Full Text] [Related]
14. β
Arif E; Medunjanin D; Solanki A; Zuo X; Su Y; Dang Y; Winkler B; Lerner K; Kamal AI; Palygin O; Cornier MA; Wolf BJ; Hunt KJ; Lipschutz JH
Am J Physiol Renal Physiol; 2024 Jan; 326(1):F20-F29. PubMed ID: 37916289
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and healthcare resource utilization in patients with chronic obstructive pulmonary disease in Hong Kong.
Ko FWS; Xu X; Chau C; Navarro A; Hui DSC; Milea D
Respir Med; 2024 Feb; 222():107516. PubMed ID: 38184091
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Recurrent Exacerbations in the General-Practitioner-Based Swiss Chronic Obstructive Pulmonary Disease (COPD) Cohort.
Abu Hussein NS; Giezendanner S; Urwyler P; Bridevaux PO; Chhajed PN; Geiser T; Joos Zellweger L; Kohler M; Miedinger D; Pasha Z; Thurnheer R; von Garnier C; Leuppi JD
J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892832
[TBL] [Abstract][Full Text] [Related]
17. Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study.
Hahn B; Stanford RH; Goolsby Hunter A; Essoi B; White J; Ray R
Pulm Ther; 2019 Jun; 5(1):69-80. PubMed ID: 32026428
[TBL] [Abstract][Full Text] [Related]
18. [Perioperative Rehabolotation Usefulness in Preventing Complications].
Usuda J
Kyobu Geka; 2023 Sep; 76(10):878-882. PubMed ID: 38056855
[TBL] [Abstract][Full Text] [Related]
19. New Perspectives for Mucolytic, Anti-inflammatory and Adjunctive Therapy with 1,8-Cineole in COPD and Asthma: Review on the New Therapeutic Approach.
Juergens LJ; Worth H; Juergens UR
Adv Ther; 2020 May; 37(5):1737-1753. PubMed ID: 32200535
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Symptom Burden in Patients with COPD on LAMA Monotherapy: Multivariable Analysis of a Claims-Linked Survey Study.
Hahn B; Stanford RH; Hunter AG; White J; Essoi B; Ray R
Pulm Ther; 2019 Dec; 5(2):179-190. PubMed ID: 32026410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
